Microscopic Polyangiitis

Back

Practice Essentials

Microscopic polyangiitis (MPA) is a vasculitis of small vessels. Patients frequently present with renal manifestations, but systemic manifestations, arthritis, mononeuritis multiplex, and other signs and symptoms are also common.[1, 2]  (See Presentation and Workup.)

Vasculitis in small vessels, including arterioles, capillaries, and venules, a characteristic of MPA, is absent in polyarteritis nodosa. This absence is the proposed distinguishing feature between those two disorders. Granulomatosis with polyangiitis (Wegener granulomatosis, GPA), MPA, and eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome, EGPA) comprise a category of small vessel vasculitis related to antineutrophil cytoplasmic antibodies (ANCAs) and are characterized by a paucity of immune deposits.

MPA and GPA seem to be part of a clinical spectrum. However, an absence of granuloma formation and sparing of the upper respiratory tract are features of MPA. These features help to distinguish MPA from GPA, although the two conditions are occasionally difficult to distinguish.

The image below depicts pulmonary alveolar capillaritis.



View Image

Pulmonary alveolar capillaritis.

Immunosuppressive medications are used to control MPA.[3] The choice of agents depends in part on the extent of disease, the rate of progression, and the degree of inflammation. See Treatment and Medication.

Background

MPA was initially considered as a microscopic form of polyarteritis nodosa. In 1990, the American College of Rheumatology developed classification criteria for several types of systemic vasculitis but did not distinguish between polyarteritis nodosa and microscopic polyarteritis nodosa.[4]

In 1994, a group of experts held an international consensus conference in Chapel Hill, North Carolina, to attempt to redefine the classification of small-vessel vasculitides.[5, 6] A second International Chapel Hill Consensus Conference was held in 2012.[7] The conference recommended categorizing small-vessel vasculitis as follows:

In addition, the conference recommended adding the following categories of vasculitis:

Classification criteria

The American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR) have published classification criteria for MPA. The criteria are intended tobe used for enrolling patients in studies, not for clinical diagnosis. The classification criteria should be applied after a diagnosis of small- or medium-vessel vasculitis has been made, and alternative disorders mimicking vasculitis have been excluded.[8]

Criteria and assigned scores are as follows[8] :

For the purposes of classification, a patient with a total score of 5 or more is said to have MPA. These criteria have a sensitivity of 91% and a specificity of 94%.[8]

Pathophysiology

Vasculitis is inflammation of the vessel walls. This may lead to necrosis and bleeding. MPA is characterized by pauci-immune, necrotizing, small-vessel vasculitis without clinical or pathological evidence of granulomatous inflammation.

Etiology

Based on current understanding of the inflammatory response, cytokine-mediated changes in the expression and function of adhesion molecules coupled with inappropriate activation of leukocytes and endothelial cells are postulated to be the primary factors influencing the degree and location of vessel damage in the vasculitis syndromes. However, the stimuli that initiate these pathologic inflammatory changes are not well understood.

ANCA may play a role in the pathogenesis of MPA.

Case reports have described an association of MPA with medications (eg, propylthiouracil, hydralazine, rifampicin, ethambutol) and with diseases such as primary biliary cirrhosis.[9, 10, 11]

Epidemiology

With the increased availability of ANCA testing, reported cases of MPA have also risen. A 20-year population-based study in Rochester, Minnesota estimated the incidence of MPA at 1.6 per 100,000 persons.[12]

Internationally, the incidence is approximately two cases per 100,000 persons in the United Kingdom. In Sweden and Germany, the incidence is estimated to be 1.3 per 100,000 persons.[13, 14]

The median age of onset is approximately 50 years. MPA is more common in White persons than Black persons; males are affected slightly more frequently than females.

Prognosis

With treatment, 90% of patients with MPA improve and 75% achieve complete remission. The 5-year survival rate is approximately 75%. MPA carries a worse long-term survival rate than granulomatosis with polyangiitis (GPA) or Churg-Strauss syndrome, probably because of kidney involvement at disease onset.

Of patients with MPA, 30% relapse in 1-2 years. Oh et al reported that neither myeloperoxidase (MPO)-ANCA nor proteinase 3 (PR3)-ANCA positivity at diagnosis affected prognosis. However, risk of relapse was significantly higher in patients with chest and renal manifestations, Birmingham vasculitis activity score  ≥13.5, or five factor score ≥1.[15]

Long-term damage in a study of 296 patients with MPA or GPA, as measured with the Vasculitis Damage Index (VDI), was associated with the severity of initial disease, older age, the number of relapses, and duration of glucocorticoid treatment. Patients were followed for 7 years post-diagnosis. Mean duration of glucocorticoid treatment was 40.4 months.[16]

In another study of 151 patients with ANCA-associated vasculitis, patients presenting with pulmonary involvement at baseline had higher damage and disease activity scores at 6, 12 and 24 months follow-up. Patients presenting with lung involvement had an increased risk of developing cardiovascular and kidney involvement and were more likely to develop pulmonary fibrosis.[17]

Complications of vasculitis depend on the particular organ system involvement. One of the most significant complications of treatment is bladder cancer. Of patients treated with cyclophosphamide, 5% develop bladder cancer after 10 years and 16% develop bladder cancer after 15 years.

One study reviewed cardiovascular outcomes during long-term follow-up of patients with MPA and GPA in the first 4 European Vasculitis Study Group trials. A model was developed and validated to predict those at risk for a cardiovascular event. Older age, diastolic hypertension, and positive PR3-ANCA status were found to be independent determinants of cardiovascular outcomes. Within 5 years of diagnosis, 14% of patients experienced a cardiovascular event.[18]

The French Vasculitis Study Group Relapse Score (FRS) was developed to predict the probability of relapse in patients with MPA or GPA.[19] The FRS assigns each of the following features 1 point:

In the validation cohort, the FRS score and associated 5-year relapse risk was as follows:

Patient Education

Patients with MPA should be aware of the severity of the disease and the risk of recurrence. Compliance with medications and follow-up visits is critical.

History

Constitutional manifestations of microscopic polyangiitis (MPA) include the following:

Renal manifestations are seen in more than 80% of patients and fall on a spectrum from asymptomatic hematuria to necrotizing crescentic GN causing end-stage kidney disease[20] . 

Other manifestations of MPA include the following:

Physical Examination

The physical examination findings include fever and the manifestations of specific organ system involvement. A dermato-pulmonary-renal syndrome is the feature of the disease.

Skin findings are as follows:

Compared to GPA and EGPA, MPA is more closely associated with livedoid changes, and vascular inflammation tends to be deeper in the skin; extravascular granulomas are not present.[21]

Respiratory findings in the lower respiratory system include pulmonary rales and respiratory distress. In the upper respiratory tract, sinusitis is less frequent than in granulomatosis with polyangiitis (Wegener granulomatosis).

Cardiovascular findings include the following:

Gastrointestinal findings include the following:

Ocular findings (1%) include the following:

Renal findings comprise signs of uremia in advanced renal failure; 8% of patients with MPA present with renal failure and require hemodialysis. 

Musculoskeletal findings include synovitis and arthritis.

Neurologic findings are as follows:

Orchitis is present in 2% of male patients.

Laboratory Studies

The complete blood cell count (CBC) in patients with microscopic polyangiitis (MPA) demonstrates leukocytosis and a normocytic anemia. The erythrocyte sedimentation rate (ESR) is elevated.

Kidney function test results are as follows:

Antineutrophil cytoplasmic antibody (ANCA) test results are as follows:

Blood cultures may be performed to rule out bacterial endocarditis. On complement testing, C3 and C4 levels are normal.

Imaging Studies

Chest radiograph findings are as follows:



View Image

Pulmonary alveolar capillaritis.

Other imaging studies may be indicated for the complications of the disease and specific organ system involvement. For example, abdominal computed tomography may be indicated for suspected pancreatitis, or mesenteric angiography to differentiate MPA from polyarteritis nodosa.

Other Tests

Other tests may be ordered according to the specific organ system involved, as follows:

Procedures

Biopsy

The following biopsies may be useful:

The results of a retrospective study suggest muscle biopsy may be helpful for the diagnosis of systemic vasculitides even in the absence of myalgias or creatine phosphokinase (CPK) elevation.[22]

Histologic Findings

Pathologically, microscopic polyangiitis (MPA) may cause necrotizing arteritis that is histologically identical to that caused by polyarteritis nodosa.

According to the Chapel Hill consensus conference on the classification of small vessel vasculitis, polyarteritis nodosa and MPA are distinguished pathologically by the absence of vasculitis in vessels other than arteries in patients with polyarteritis nodosa and the presence of vasculitis in vessels smaller than arteries, such as arterioles, venules, and capillaries, in patients with MPA.

Because of sparing of muscular and larger vessels in MPA, macroscopic infarcts similar to those seen in polyarteritis nodosa are uncommon. Histologically, segmental fibrinoid necrosis of the media may be present, but in some, the change is limited to infiltration with neutrophils, which become fragmented as they follow the vessel wall (leukocytoclasia). The term leukocytoclastic angiitis is given to such lesions, most commonly found in postcapillary venules.

Immunoglobulins and complement components may be present in the vascular lesions of the skin. The paucity of immunoglobulin is demonstrable using immunofluorescence microscopy (ie, pauci-immune injury).

The glomerulonephritis in MPA is characterized by focal necrosis, crescent formation, and the absence or paucity of immunoglobulin deposits. Pulmonary manifestation is in the form of pulmonary alveolar capillaritis. Biopsy of the muscle and sural nerve may reveal necrotizing vasculitis in small and medium vessels.



View Image

Histopathology of alveolar hemorrhage in alveolar capillaritis.



View Image

Crescentic glomerulonephritis.



View Image

Focal segmental glomerulonephritis.



View Image

Histopathology of leukocytoclastic angiitis.

Approach Considerations

Treatment of microscopic polyangiitis (MPA) is principally with corticosteroids and other immunosuppressive agents and consists of induction and maintenance of remission.The treatment of relapsed MPA is the same as that of remission induction. Intravenous immunoglobulin has been used in treatment of refractory disease.[23]

MPA can manifest as a mild systemic vasculitis with mild kidney insufficiency, or it can manifest as a full-blown acute disease with rapid deterioration of kidney function and respiratory failure due to pulmonary capillaritis. The choice of medication depends in part on the extent of disease, the rate of progression, and the degree of inflammation.

Induction of Remission

Induction of remission in MPA is customarily achieved with cyclophosphamide and prednisone; glucocorticoid monotherapy is not recommended because of lower remission rates. Cyclophosphamide is started at 1.5-2 mg/kg/d. The patient should be monitored for leukocytopenia and neutropenia. Prednisone is started at 1 mg/kg/d and is continued for 1 month. If significant improvement is seen, the prednisone dose is decreased by 5 mg/wk. Once the dosage of 10 mg/d is reached, the next taper can be to 10 mg every other day. After complete remission, the maintenance phase is started.

In the PEXIVAS trial, which compared two regimens of oral glucocorticoids in patients with severe MPA or granulomatosis with polyangiitis (Wegener granulomatosis; GPA) a reduced-dose regimen proved noninferior to a standard-dose regimen with respect to the risk of death or end-stage kidney disease, and resulted in a lower risk of serious infections in the first year of treatment. The reduced-dose regimen in PEXIVAS provides approximately 55% of the standard-dose regimen over the first 6 months.[24]  American College of Rheumatology/Vasculitis Foundation guidelines conditionally recommend a reduced-dose glucocorticoid regimen over a standard-dose regimen for remission induction in MPA and GPA.[25]

The European Vasculitis Study Group reported that in the first year of therapy for ANCA-associated vasculitis (AAV), 59% of deaths were due to therapy-associated adverse events (eg, leukopenia, infection).[26] The risk of adverse effects has prompted a search for alternatives to glucocorticoids.

The the C5a receptor inhibitor avacopan was developed for treatment of AAV. The randomized, controlled ADVOCATE trial compared  avacopan with prednisone (both given in combination with either cyclophosphamide, followed by azathioprine, or rituximab) in 331 patients with AAV, and found that avacopan was noninferior to prednisone at week 24 and superior at week 52 for achieving complete remission.[27] Avacopan is approved by the US Food and Drug Administration (FDA) for adjunctive treatment of severe MPA and GPA, in combination with glucocorticoids, and the European Alliance of Associations for Rheumatology (EULAR) suggests considering avacopan as part of a strategy to reduce exposure to glucocorticoids in such patients.[28]

Avacopan is not approved as a substitute for steroids. However, in a small retrospective study by Gabilan et al of patients with de novo or relapsing AAV who presented with rapidly progressive glomerulonephritis, treatment with avacopan plus rituximab led to a high rate of AAV remission, with rapid control of kidney inflammation; glucocorticoids were either stopped or tapered rapidly in these patients.[29]

Other regimens that have been studied for remission induction in MPA include mycophenolate mofetil versus cyclophosphamide and intravenous immunoglobulin in refractory cases.[30] In cases involving life-threatening alveolar capillaritis with pulmonary alveolar hemorrhage, plasmapheresis in addition to intravenous cyclophosphamide and pulse doses of steroids may be used.

For induction of remission in patients with milder manifestations of MPA, a combination of methotrexate and prednisone can be used. However, a significantly higher relapse rate was observed with this combination than with the combination of cyclophosphamide and prednisone.[31] Nevertheless, given the value of limiting the duration of exposure to cyclophosphamide, this regimen offers the advantage of methotrexate's superior safety profile, compared with that of cyclophosphamide, and (because the higher rate of relapse in that study occurred after treatment discontinuation) the likelihood that longer duration of maintenance therapy will result in lower relapse rates.[32]

In 2011, the US Food and Drug Administration (FDA) approved rituximab to treat MPA and GPA. The safety and effectiveness of rituximab was demonstrated in a single controlled trial by the RAVE-ITN Research Group, in which 197 adults with MPA or GPA were randomly assigned to receive either rituximab (375 mg/m2/wk for 4 wk) plus daily prednisone, or cyclophosphamide (2 mg/kg/d) orally plus daily prednisone to induce remission.[33] Prednisone was tapered off. The primary endpoint was remission of disease without use of prednisone at 6 months. After 6 months, 64% of patients treated with rituximab had complete remission compared with 53% of those treated with cyclophosphamide. In 2019, the indication was expanded to include children aged 2 years or older. 

Maintenance of Remission

For remission maintenance, the preference is to replace cyclophosphamide, which has high toxicity, with either methotrexate or azathioprine.[34, 35] However, if the serum creatinine concentration is greater than 2 mg/dL, methotrexate is not an option. At this phase, prednisone is continued and cyclophosphamide is replaced with azathioprine at 2 mg/kg/d for 12 months. After a year, the dose of azathioprine is decreased to 1.5 mg/kg/d. If methotrexate is used for maintenance treatment, it can be started at 0.3 mg/kg once a week, with the maximum dose of 15 mg/wk. This is increased by 2.5 mg/wk (maximum 20 mg/wk).

This phase is continued for 12-24 months. Prednisone can be continued at 10 mg/d or every other day.

Analysis of long-term outcomes in 112 patients enrolled in the WEGENT trial confirmed that methotrexate or azathioprine are comparable treatment options for maintaining remission of MPA. The 10-year overall survival rates were 75.1% in patients receiving azathioprine and 79.9% in those receiving methotrexate (P = 0.56), while relapse-free survival rates were 26.3% and 33.5% (P = 0.29), respectively.[36]

A followup study by the RAVE-ITN Research Group demonstrated that a single course of rituximab was as effective as continuous conventional immunosuppressive therapy for inducing and maintaining remission for 18 months. At 18 months, 39% of the patients in the rituximab group had maintained complete remissions, compared with 33% of the patients who received cyclophosphamide for 3 to 6 months followed by azathioprine for 12 to 15 months.[37]

The French Vasculitis Study Group reported that rituximab was more effective than azathioprine for maintaining remission in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis. In this study, 115 patients with newly diagnosed or relapsing GPA, MPA, or renal-limited ANCA-associated vasculitis in complete remission after a cyclophosphamide-glucocorticoid regimen were randomly assigned to receive either 500 mg of rituximab on days 0 and 14 and at months 6, 12, and 18 after study entry or daily azathioprine until month 22. At month 28, 17 patients (29%) in the azathioprine group had experienced major relapse, compared with three patients (5%) in the rituximab group (hazard ratio for relapse, 6.61; P = 0.002).17 On continued follow-up to 60 months, major relapse-free survival rates were 71.9% with rituximab versus 49.4% with azathioprine (P=0.003); overall survival rates were 100% with rituximab versus 93.0% with azathioprine (P=0.045).[38]

Another French Vasculitis Study Group trial compared fixed-schedule and individually tailored rituximab regimens for maintaining remission of ANCA-associated vasculitis, and found that relapse rates did not differ significantly between the two approaches, while patients on individually tailored regimens received fewer rituximab infusions. Patients on individually tailored regimens received an initial 500-mg rituximab infusion and then underwent testing every 3 months, with rituximab reinfusion only when CD19+ B lymphocytes or ANCA had reappeared or the ANCA titer rose markedly. [39]

The long-term safety of rituximab in MPA was documented in a phase IV, open-label, prospective 4-year observational registry of adult patients with  MPA or GPA. The safety profile of rituximab proved consistent with that of shorter-term treatment and with rituximab's known safety profile in other autoimmune diseases.[40]

Other therapies include the following:

Consultations

A rheumatologist would be the main consultant who helps with the diagnosis and immunosuppressive therapy. Additional consultations would be based on the specific organ system involvement, as follows:

Long-Term Monitoring

Patients with microscopic polyangiitis (MPA) need to be monitored very closely at a rheumatology clinic. Patients need to take immunosuppressive medications for a long time, at least for a year. Clinical status and the erythrocyte sedimentation rate (ESR) should be monitored.

The level of ANCA may be used to monitor disease activity. However, ANCA levels do not correlate consistently with the disease activity. In one study, ANCA levels became undetectable in 83% of patients after treatment; however, ANCA levels increased in 57% of patients at a mean period of 7.8 weeks prior to relapse. Reappearance of anti-MPO antibodies has positive predictive value for relapse.[47, 48]

Medication Summary

Various immunosuppressive agents are used in the treatment of microscopic polyangiitis (MPA). The choice of agents depends on the treatment phase (induction versus maintenance of remission) and disease severity.

Methylprednisolone (Adlone, Medrol, Solu-Medrol)

Clinical Context:  Steroids ameliorate effects immune reactions and may limit biphasic anaphylaxis.

Prednisone (Deltasone, Orasone, Sterapred)

Clinical Context:  Immunosuppressant for treatment of autoimmune disorders; may decrease inflammation by reversing increased capillary permeability and suppressing PMN activity. Stabilizes lysosomal membranes and suppresses lymphocytes and antibody production.

Class Summary

First line of treatment for induction of remission and usually for maintenance. For induction of remission, use IV methylprednisolone. For maintenance, use prednisone.

Cyclophosphamide (Cytoxan, Neosar)

Clinical Context:  Chemically related to nitrogen mustards.

As an alkylating agent, the mechanism of action of the active metabolites may involve cross-linking of DNA, which may interfere with growth of normal and neoplastic cells.

Rituximab (Rituxan)

Clinical Context:  Chimeric murine/human monoclonal antibody directed against the CD20 antigen found on surface of B-lymphocytes. It is indicated in combination with glucocorticoids for treatment of adult and pediatric patients aged 2 years or older with granulomatosis with polyangiitis (GPA; Wegener granulomatosis) or microscopic polyangiitis (MPA).

Methotrexate (Folex PFS, Rheumatrex)

Clinical Context:  Should not be used if serum creatinine clearance is >2.0 mg/dL.

Unknown mechanism of action in treatment of inflammatory reactions; may affect immune function. Ameliorates symptoms of inflammation (eg, pain, swelling, stiffness). Adjust dose gradually to attain satisfactory response. An alternative form of less toxic therapy only for localized and nonaggressive disease is combination of MTX and prednisone.

Azathioprine (Imuran)

Clinical Context:  Immunosuppressive agent; antagonizes purine metabolism and inhibits synthesis of DNA, RNA, and proteins. May decrease proliferation of immune cells, which results in lower autoimmune activity.

Class Summary

These agents inhibit immune reactions that result from diverse stimuli.

Avacopan (Tavneos)

Clinical Context:  Complement 5a receptor (C5aR) antagonist that inhibits the interaction between C5aR and the anaphylatoxin C5a. Indicated as adjunctive treatment of severe active antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis) in combination with glucocorticoids.

What is microscopic polyangiitis (MPA)?How is microscopic polyangiitis (MPA) categorized?What is the pathophysiology of microscopic polyangiitis (MPA)?What causes microscopic polyangiitis (MPA)?What is the prevalence of microscopic polyangiitis (MPA)?What is the prognosis of microscopic polyangiitis (MPA)?Which patient groups have the highest prevalence of microscopic polyangiitis (MPA)?What are the signs and symptoms of microscopic polyangiitis (MPA)?Which physical findings are characteristic of microscopic polyangiitis (MPA)?Which dermatologic findings are characteristic of microscopic polyangiitis (MPA)?Which respiratory findings are characteristic of microscopic polyangiitis (MPA)?Which cardiovascular findings are characteristic of microscopic polyangiitis (MPA)?Which GI findings are characteristic of microscopic polyangiitis (MPA)?Which ocular findings are characteristic of microscopic polyangiitis (MPA)?Which renal findings are characteristic of microscopic polyangiitis (MPA)?What are musculoskeletal findings are characteristic of microscopic polyangiitis (MPA)?Which neurologic findings are characteristic of microscopic polyangiitis (MPA)?What are the differential diagnoses for Microscopic Polyangiitis?Which complete blood cell count (CBC) findings suggest microscopic polyangiitis (MPA)?Which findings on renal testing suggest microscopic polyangiitis (MPA)?Which antineutrophil cytoplasmic antibody (ANCA) test results suggest microscopic polyangiitis (MPA)?What is the role of blood cultures in the diagnosis of microscopic polyangiitis (MPA)?Which chest radiograph findings suggest microscopic polyangiitis (MPA)?What other imaging studies are indicated in the diagnosis of microscopic polyangiitis (MPA)?What is the role of CT scanning in the evaluation of microscopic polyangiitis (MPA)?What is the role of biopsy in the diagnosis of microscopic polyangiitis (MPA)?Which histologic findings are characteristic of microscopic polyangiitis (MPA)?How is microscopic polyangiitis (MPA) treated?How is remission induced in the treatment of microscopic polyangiitis (MPA)?How is remission maintained in the treatment of microscopic polyangiitis (MPA)?Which medications are used in the treatment of microscopic polyangiitis (MPA)?Which specialist consultations are beneficial to patients with microscopic polyangiitis (MPA)?What is the role of immunosuppressive agents in the treatment of microscopic polyangiitis (MPA)?Which medications in the drug class Immunosuppressive agents are used in the treatment of Microscopic Polyangiitis?Which medications in the drug class Corticosteroids are used in the treatment of Microscopic Polyangiitis?

Author

Mehran Farid-Moayer, MD, Adjunct Clinical Faculty, Department of Psychiatry, Sleep Disorders Clinic, Stanford Medical Center

Disclosure: Nothing to disclose.

Coauthor(s)

Spencer T Lowe, MD, Rheumatologist, Mills-Peninsula Medical Center, Sutter Health

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Elliot Goldberg, MD, Dean of the Western Pennsylvania Clinical Campus, Professor, Department of Medicine, Lewis Katz School of Medicine at Temple University

Disclosure: Nothing to disclose.

Chief Editor

Vecihi Batuman, MD, FASN, Professor of Medicine, Section of Nephrology-Hypertension, Deming Department of Medicine, Tulane University School of Medicine

Disclosure: Nothing to disclose.

Additional Contributors

Bryan L Martin, DO, Associate Dean for Graduate Medical Education, Designated Institutional Official, Associate Medical Director, Director, Allergy Immunology Program, Professor of Medicine and Pediatrics, Ohio State University College of Medicine

Disclosure: Nothing to disclose.

References

  1. Hashmi MF, Jain V, Tiwari V. Microscopic Polyangiitis. 2023 Jan. [View Abstract]
  2. Chung SA, Seo P. Microscopic polyangiitis. Rheum Dis Clin North Am. 2010 Aug. 36 (3):545-58. [View Abstract]
  3. Berti A, Cornec D, Dua AB. Treatment Approaches to Granulomatosis with Polyangiitis and Microscopic Polyangiitis. Rheum Dis Clin North Am. 2023 Aug. 49 (3):545-561. [View Abstract]
  4. Fries JF, Hunder GG, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum. 1990 Aug. 33(8):1135-6. [View Abstract]
  5. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994 Feb. 37(2):187-92. [View Abstract]
  6. Lightfoot RW, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum. 1990 Aug. 33(8):1088-93. [View Abstract]
  7. Jennette JC. Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol. 2013 Oct. 17 (5):603-606. [View Abstract]
  8. [Guideline] Suppiah R, Robson JC, Grayson PC, Ponte C, Craven A, Khalid S, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Ann Rheum Dis. 2022 Mar. 81 (3):321-326. [View Abstract]
  9. Seligman VA, Bolton PB, Sanchez HC, Fye KH. Propylthiouracil-induced microscopic polyangiitis. J Clin Rheumatol. 2001 Jun. 7(3):170-4. [View Abstract]
  10. Amezcua-Guerra LM, Prieto P, Bojalil R, Pineda C, Amigo MC. Microscopic polyangiitis associated with primary biliary cirrhosis: a causal or casual association?. J Rheumatol. 2006 Nov. 33(11):2351-3. [View Abstract]
  11. Kuwabara G, Yamada K, Tanaka K, Nozuchi S, Imoto W, Shibata W, et al. Muscle Biopsy-proven Drug-induced Microscopic Polyangiitis in a Patient with Tuberculosis. Intern Med. 2023 Jan 1. 62 (1):129-133. [View Abstract]
  12. Berti A, Cornec D, Crowson CS, Specks U, Matteson EL. The Epidemiology of Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis in Olmsted County, Minnesota: A Twenty-Year US Population-Based Study. Arthritis Rheumatol. 2017 Dec. 69 (12):2338-2350. [View Abstract]
  13. Rathmann J, Segelmark M, Englund M, Mohammad AJ. Stable incidence but increase in prevalence of ANCA-associated vasculitis in southern Sweden: a 23-year study. RMD Open. 2023 Mar. 9 (1):[View Abstract]
  14. Hellmich B, Lamprecht P, Spearpoint P, Götte D, Deichmann A, Buchholz I, et al. New insights into the epidemiology of ANCA-associated vasculitides in Germany: results from a claims data study. Rheumatology (Oxford). 2021 Oct 2. 60 (10):4868-4873. [View Abstract]
  15. Oh YJ, Ahn SS, Park ES, Jung SM, Song JJ, Park YB, et al. Chest and renal involvements, Birmingham vascular activity score more than 13.5 and five factor score (1996) more than 1 at diagnosis are significant predictors of relapse of microscopic polyangiitis. Clin Exp Rheumatol. 2017 Jan 19. [View Abstract]
  16. Robson J, Doll H, Suppiah R, Flossmann O, Harper L, Höglund P, et al. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology (Oxford). 2014 Sep 8. [View Abstract]
  17. Hassan TM, Hassan AS, Igoe A, Logan M, Gunaratnam C, McElvaney NG, et al. Lung involvement at presentation predicts disease activity and permanent organ damage at 6, 12 and 24 months follow - up in ANCA - associated vasculitis. BMC Immunol. 2014 May 27. 15:20. [View Abstract]
  18. Suppiah R, Judge A, Batra R, Flossmann O, Harper L, Höglund P, et al. A model to predict cardiovascular events in patients with newly diagnosed wegener's granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken). 2011 Jan 14. [View Abstract]
  19. Samson M, Devilliers H, Thietart S, Charles P, Pagnoux C, Cohen P, et al. Score to assess the probability of relapse in granulomatosis with polyangiitis and microscopic polyangiitis. RMD Open. 2023 Mar. 9 (1):[View Abstract]
  20. Massicotte-Azarniouch D, Herrera CA, Jennette JC, Falk RJ, Free ME. Mechanisms of vascular damage in ANCA vasculitis. Semin Immunopathol. 2022 May. 44 (3):325-345. [View Abstract]
  21. Gibson LE. Cutaneous manifestations of antineutrophil cytoplasmic antibody-associated vasculitis (AAV): a concise review with emphasis on clinical and histopathologic correlation. Int J Dermatol. 2022 Dec. 61 (12):1442-1451. [View Abstract]
  22. Hervier B, Durant C, Masseau A, Ponge T, Hamidou M, Mussini JM. Use of muscle biopsies for diagnosis of systemic vasculitides. J Rheumatol. 2011 Mar. 38(3):470-4. [View Abstract]
  23. Crickx E, Machelart I, Lazaro E, et al. Intravenous Immunoglobulin as an Immunomodulating Agent in Antineutrophil Cytoplasmic Antibody-Associated Vasculitides: A French Nationwide Study of Ninety-Two Patients. Arthritis Rheumatol. 2016 Mar. 68 (3):702-12. [View Abstract]
  24. Walsh M, et al; PEXIVAS Investigators. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. N Engl J Med. 2020 Feb 13. 382 (7):622-631. [View Abstract]
  25. [Guideline] Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Care Res (Hoboken). 2021 Aug. 73 (8):1088-1105. [View Abstract]
  26. Little MA, Nightingale P, Verburgh CA, Hauser T, De Groot K, Savage C, et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis. 2010 Jun. 69 (6):1036-43. [View Abstract]
  27. Jayne DRW, Merkel PA, Schall TJ, Bekker P, ADVOCATE Study Group. Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med. 2021 Feb 18. 384 (7):599-609. [View Abstract]
  28. [Guideline] Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2023 Mar 16. 28 (9):2756-2767. [View Abstract]
  29. Gabilan C, Pfirmann P, Ribes D, Rigothier C, Chauveau D, Casemayou A, et al. Avacopan as First-Line Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Steroid-Sparing Option. Kidney Int Rep. 2022 May. 7 (5):1115-1118. [View Abstract]
  30. Springer JM, Kalot MA, Husainat NM, Byram KW, Dua AB, James KE, et al. Granulomatosis With Polyangiitis and Microscopic Polyangiitis: A Systematic Review and Meta-Analysis of Benefits and Harms of Common Treatments. ACR Open Rheumatol. 2021 Mar. 3 (3):196-205. [View Abstract]
  31. Faurschou M, Westman K, Rasmussen N, de Groot K, Flossmann O, Höglund P, et al. Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012 Oct. 64 (10):3472-7. [View Abstract]
  32. Langford CA, Hoffman GS. Methotrexate remains a valuable option for remission induction of nonsevere antineutrophil cytoplasmic antibody-associated vasculitis: comment on the article by Faurschou et al. Arthritis Rheum. 2013 Mar. 65 (3):843. [View Abstract]
  33. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010 Jul 15. 363(3):221-32. [View Abstract]
  34. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003 Jul 3. 349(1):36-44. [View Abstract]
  35. Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008 Dec 25. 359 (26):2790-803. [View Abstract]
  36. Puéchal X, Pagnoux C, Perrodeau É, et al. Long-Term Outcomes Among Participants in the WEGENT Trial of Remission-Maintenance Therapy for Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis. Arthritis Rheumatol. 2016 Mar. 68 (3):690-701. [View Abstract]
  37. Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013 Aug 1. 369(5):417-27. [View Abstract]
  38. Terrier B et al; French Vasculitis Study Group. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Ann Rheum Dis. 2018 May 3. [View Abstract]
  39. Charles P et al; French Vasculitis Study Group. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018 Apr 25. [View Abstract]
  40. Merkel PA, Niles JL, Mertz LE, Lehane PB, Pordeli P, Erblang F. Long-Term Safety of Rituximab in Granulomatosis With Polyangiitis and in Microscopic Polyangiitis. Arthritis Care Res (Hoboken). 2021 Sep. 73 (9):1372-1378. [View Abstract]
  41. Reinhold-Keller E, De Groot K, Rudert H, Nölle B, Heller M, Gross WL. Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. QJM. 1996 Jan. 89(1):15-23. [View Abstract]
  42. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med. 1996 Jul 4. 335(1):16-20. [View Abstract]
  43. Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum. 2004 Apr 15. 51(2):278-83. [View Abstract]
  44. Nowack R, Göbel U, Klooker P, Hergesell O, Andrassy K, van der Woude FJ. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol. 1999 Sep. 10(9):1965-71. [View Abstract]
  45. Iatrou C, Zerbala S, Revela I, Spanou E, Marinaki S, Nakopoulou L, et al. Mycophenolate mofetil as maintenance therapy in patients with vasculitis and renal involvement. Clin Nephrol. 2009 Jul. 72(1):31-7. [View Abstract]
  46. Haubitz M, Koch KM, Brunkhorst R. Cyclosporin for the prevention of disease reactivation in relapsing ANCA-associated vasculitis. Nephrol Dial Transplant. 1998 Aug. 13 (8):2074-6. [View Abstract]
  47. Terrier B, Saadoun D, Sène D, Ghillani P, Amoura Z, Deray G, et al. Antimyeloperoxidase antibodies are a useful marker of disease activity in antineutrophil cytoplasmic antibody-associated vasculitides. Ann Rheum Dis. 2009 Oct. 68(10):1564-71. [View Abstract]
  48. Watanabe H et al, for Japan Research Committee of the Ministry of Health Labour,Welfare for Intractable Vasculitis (JPVAS) Research Committee of Intractable Renal Disease of the Ministry of Health Labour, Welfare of Japan. Association between reappearance of myeloperoxidase-antineutrophil cytoplasmic antibody and relapse in antineutrophil cytoplasmic antibody-associated vasculitis: Subgroup analysis of nationwide prospective cohort studies. Arthritis Rheumatol. 2018 May 22. [View Abstract]

Pulmonary alveolar capillaritis.

Leukocytoclastic angiitis.

Pulmonary alveolar capillaritis.

Histopathology of alveolar hemorrhage in alveolar capillaritis.

Crescentic glomerulonephritis.

Focal segmental glomerulonephritis.

Histopathology of leukocytoclastic angiitis.

Pulmonary alveolar capillaritis.

Histopathology of alveolar hemorrhage in alveolar capillaritis.

Crescentic glomerulonephritis.

Focal segmental glomerulonephritis.

Histopathology of leukocytoclastic angiitis.

Leukocytoclastic angiitis.